Novo Nordisk A/S (NYSE:NVO) Trading Down 1.1% - Should You Sell?

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) fell 1.1% during mid-day trading on Monday . The stock traded as low as $77.82 and last traded at $77.94. 9,865,736 shares traded hands during mid-day trading, an increase of 3% from the average session volume of 9,598,048 shares. The stock had previously closed at $78.83.

Analyst Ratings Changes

Several research firms have recently issued reports on NVO. BMO Capital Markets reduced their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, December 23rd. BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. StockNews.com lowered Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a report on Sunday, December 29th. Finally, UBS Group raised Novo Nordisk A/S from a "sell" rating to a "buy" rating in a report on Wednesday, January 8th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Trading Up 5.2 %

The stock has a market cap of $395.19 billion, a PE ratio of 26.77, a P/E/G ratio of 0.90 and a beta of 0.45. The firm has a 50-day simple moving average of $86.39 and a 200-day simple moving average of $108.48. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be paid a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is currently 47.72%.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Forum Financial Management LP grew its stake in shares of Novo Nordisk A/S by 0.9% during the fourth quarter. Forum Financial Management LP now owns 23,897 shares of the company's stock valued at $2,056,000 after buying an additional 219 shares during the last quarter. Kingstone Capital Partners Texas LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $285,000. Formidable Asset Management LLC grew its stake in shares of Novo Nordisk A/S by 116.9% during the fourth quarter. Formidable Asset Management LLC now owns 14,576 shares of the company's stock valued at $1,254,000 after buying an additional 7,857 shares during the last quarter. Parr Mcknight Wealth Management Group LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $608,000. Finally, Pacific Point Advisors LLC bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at about $1,267,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.